(Q40915483)

24 September 2017

1 reference

title

A risk-benefit assessment of losartan potassium in the treatment of hypertension (English)

1 reference

24 September 2017

1 reference

L M Burrell

1

1 reference

24 September 2017

publication date

1 January 1997

1 reference

24 September 2017

1 reference

24 September 2017

volume

16

1 reference

24 September 2017

issue

1

1 reference

24 September 2017

page(s)

56-65

1 reference

https://scigraph.springernature.com/pub.10.2165/00002018-199716010-00004

24 September 2017

exact match

0 references

cites work

Effects of Losartan on a Background of Hydrochlorothiazide in Patients With Hypertension

1 reference

12 December 2020

Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members

1 reference

12 December 2020

Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system?

1 reference

12 December 2020

Beyond ACE inhibition: new developments in drug therapy for hypertension

1 reference

12 December 2020

The angiotensin II type 1 receptor antagonists. A new class of antihypertensive drugs

1 reference

12 December 2020

Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension.

1 reference

12 December 2020

Evolution of blockade of the renin-angiotensin system

1 reference

12 December 2020

Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease

1 reference

12 December 2020

Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis

1 reference

12 December 2020

Antihypertensive efficacy and tolerability of once daily losartan potassium compared with captopril in patients with mild to moderate essential hypertension.

1 reference

12 December 2020

Angioedema induced by the angiotensin II blocker losartan

1 reference

12 December 2020

Losartan potassium as initial therapy in patients with severe hypertension

1 reference

12 December 2020

Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart

1 reference

12 December 2020

Randomised, double-blind, parallel study of the anti-hypertensive efficacy and safety of losartan potassium compared with felodipine ER in elderly patients with mild to moderate hypertension

1 reference

12 December 2020

Angiotensin II receptors and angiotensin II receptor antagonists.

1 reference

12 December 2020

Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension

1 reference

12 December 2020

Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension

1 reference

12 December 2020

Comparative effects of combination drug therapy regimens commencing with either losartan potassium, an angiotensin II receptor antagonist, or enalapril maleate for the treatment of severe hypertension

1 reference

12 December 2020

Blood pressure effects of the angiotensin II receptor blocker, losartan

1 reference

12 December 2020

Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist

1 reference

12 December 2020

Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension

1 reference

12 December 2020

Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension

1 reference

12 December 2020

Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension

1 reference

12 December 2020

Blockade of the renin-angiotensin system at different sites: effect on renin, angiotensin and aldosterone

1 reference

12 December 2020

Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension

1 reference

12 December 2020

Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components

1 reference

12 December 2020

Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients

1 reference

12 December 2020

Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans

1 reference

12 December 2020

A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension

1 reference

12 December 2020

Angiotensin receptor antagonists: focus on losartan

1 reference

12 December 2020

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

12 December 2020

Effects of modulators of the renin-angiotensin-aldosterone system on cough. Losartan Cough Study Group.

1 reference

12 December 2020

10.2165/00002018-199716010-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

24 September 2017

1023882288

0 references

1 reference